Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00522925 · ClinicalTrials.gov registry record · Phase 2
A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension
A Phase 2 study, sponsored by Ligand Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
NCT00522925 is a Phase 2 study that has completed, run by Ligand Pharmaceuticals. The registered enrollment target is 280 participants.
The verdict
NCT00522925, a Phase 2 study, has completed, sponsored by Ligand Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
Study Summary
The purpose of the study is to see if PS433540 lowers blood pressure better than placebo and to see how safe PS433540 is compared to placebo.
Interventions
- DRUG placebo
- DRUG PS433540
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00522925
The ClinicalTrials.gov registry entry for NCT00522925 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ligand Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00522925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00522925 about?
NCT00522925 is a clinical study titled "A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension". The purpose of the study is to see if PS433540 lowers blood pressure better than placebo and to see how safe PS433540 is compared to placebo.
What is the current status of trial NCT00522925?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2007-08. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00522925?
The interventions under investigation include: placebo (DRUG), PS433540 (DRUG).
Who is sponsoring clinical trial NCT00522925?
This trial is sponsored by Ligand Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.